We are excited to announce the acquisition of an exclusive licence to SCFI™- an Antibiotic Susceptibility Testing technology from the University of Bristol.
In 2017 Professor Massimo Antognozzi and his team developed Sub Cellular Fluctuation Imaging (SCFI™) which enables real-time capture of metabolic activity within bacterial cells. SCFI™ has been proven as a fast, phenotypic technique that can provide actionable information at the patient bedside. By entering an exclusive licence agreement with the University, FluoretiQ have acquired the rights to develop and commercialise this technology.
FluoretiQ CEO, Neciah Dorh commented:
“At FluoretiQ, we are passionate about bringing products to market that support the fight against AMR and sustainable prescribing of antibiotics. We will develop SCFI™ as a sister technology to NANOPLEX® to promote evidence-based and effective antibiotic treatments”
Ros Darby, our Head of Research Commercialisation and Investment said “We have been working with Fluoretiq since its inception in 2017 as a spin out company of the university. FluoretiQ has developed a revolutionary technology platform NANOPLEX® which supports their first product line aimed at diagnosing infections in fifteen minutes flat. Now we are pleased to be able to support FluoretiQ further with this licensing agreement and are proud to be supporting them in their AMR mission”.
Read the press release here: https://www.fluoretiq.com/blog/fluoretiq-secures-exclusive-licence-to-ast-technology/